Staff Scientist - Preclinical Immuno-Oncology
Staff Scientist Preclinical Immuno-Oncology
The Staff Scientist will have a background in immunology and drug development within the industry. The candidate will be a bench scientist conducting research involved in therapeutic antibody assessment in in vitro and in vivo animal models of disease. Demonstrated expertise in preclinical models for immuno-oncology (IO) is essential and additional experience in inflammation and autoimmune diseases is a plus. Understanding of IO pharmacology, toxicology and clinical immunology is a plus. Experience in IND preparation and filing processes is desirable.
- Bench scientist to design and execute functional cellular immunological assays using primary cells to support antibody discovery programs
- Design and execute in vitro and in vivo models to evaluate and characterize novel antibody therapies, PK/PD relationships, and biomarker discovery.
- Coordinate outsourcing of contract research organization for preclinical studies
- Work effectively in a highly dynamic and collaborative team environment with positive interpersonal skills.
- Utilize appropriate technology, i.e. Outlook, Excel, PowerPoint, FlowJo, GraphPad Prism, and other software applications to analyze data, create reports, and distribute results and key information.
- Coordinate tasks across multiple projects, demonstrating prioritization, organization, and planning skills
- Help impact the overall direction, capabilities and objectives for the IO group that is fully aligned with the strategy of a privately held biotech company.
- Assist in preparing annual departmental budget and manage throughout the course of the year to ensure budget is met.
- The candidate may supervise other staff while conducting studies required for supporting company projects.
- Provide support to multidisciplinary project teams and participate in strategies for product development.
- Prepare written reports and oral presentations on research projects.
- Prepare reports and other documents for submission to domestic and international regulatory agencies.
• Present study results at scientific meetings and publish results in peer-reviewed scientific journals.
• Review technical publications, articles, and abstracts to stay abreast of current developments
Education and Experience
- Ph.D. in Immunology, Cell Biology or other related, relevant areas
- Background in cancer immunology, specializing in Oncology and Immuno-Oncology, or related discipline with 4+ relevant years of industry experience.
- General training and working knowledge of pathophysiology and the molecular mechanisms of diseases
- Direct hands-on experience establishing protocols, performing complex cell-based assays and in vivo experiments that includes analysis and interpretation of results
Key technical background includes:
- Cell surface marker and signaling analytical methods (Multi-color FACS, phospho-staining, Western etc.).
- Basic cell and molecular biology techniques; cell culture, sterile technique, PCR, cloning etc.
- Qualitative and quantitative analysis of cytokine and protein levels in biological fluids and cell culture supernatants; ELISA, Luminex, etc.
- Cell proliferation, lymphoproliferative, and cytotoxicity assays
- Primary cell isolation
- Design and analysis of results from experiments generating complex data sets, e.g. high-dimensionality flow and RNA sequencing
BioAtla® is a San Diego biotech company that develops novel monoclonal antibody and cell based therapeutics using our proprietary Conditionally Active Biologics (CABs) and Comprehensive Integrated Antibody Optimization (CIAO!) platforms. These and other proprietary technologies (protected by more than 150 issued patents and patent applications) allow us to develop novel biologics (CABs) that are better drugs in multiple ways including more selective targeting of cancer tissue and improved manufacturability. Improved selectivity for the tumor microenvironment, even when the target is also found in normal tissue, not only improves safety and thus therapeutic index but also expands the universe of potential drug targets, enabling the treatment of previously untreatable cancers.